Increased plasma levels of NfL or p-tau181 blood biomarkers were found to be associated with reduced brain volumes and/or declined cognitive outcomes, suggesting that these biomarkers may have a predictive role or as a surrogate endpoint in AD trials. Here, NEFL is linked to Alzheimer disease.